Anti-HGFR/c-Met Antibody (Telisotuzumab vedotin)
Catalog No.
F2038
Anti-HGFR/c-Met Antibody (Telisotuzumab vedotin)
Featured Products
Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADC) targeting c-Met. Telisotuzumab vedotin is conjugated with Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used in cancer research.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
146.1 kDa
Dry ice
1714088-51-3
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
ABBV-399
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P08581
Human
MMAE
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
The drug-to-antibody ratio (DAR) of the Anti-HGFR / c-Met Reference Antibody (Telisotuzumab vedotin) is 4.16.
HGFR / c-Met
Please avoid freeze-thaw cycles.